SBIR/STTR Research Award

Pillar and perfusion well plate platforms for reproducible organoid culture from iPSC

Award identifier b1f5d714b06068064721aad9c97986f2a7c3a7d74e4b33b8d6af4518d6fd845fAwarding agency Department of Health and Human Services · National Institutes of Health

Award amount

$837,888

Program and phase

SBIR · Phase II – Direct to Phase II

Award year

2020

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
National Institutes of Health
Recipient company
Bioprinting Laboratories Inc.
Proposal award date
2020-07-15
Contract end date
2022-06-30
UEI
E88EGXJKKL27
Solicitation number
GM19-001
Topic code
100

Research abstract

Project Summary/AbstractThere is a critical need for improved in vitro disease modeling to rapidly advance therapeutic drug candidates to preclinical evaluation or to prioritize potential environmental toxicants. Recently, there have been significant advances made in in vitro disease models, including human mini-tissues derived from pluripotent stem cells (PSCs) and progenitor cells (a.k.a., organoid), bioprinted human tissue constructs with cells obtained from patients (a.k.a., 3D bioprinting), and multi-layered cells in microfluidic chips (a.k.a., organ-on-chip). These new and innovative technologies, however, still lack enough throughput and user friendliness to enable rapid identification of high-quality therapeutic candidates, particularly when a disease involves multiple organ interactions. To address these challenges, we propose to leverage our unique “miniature three-dimensional (3D) bioprinting” technology and associated pillar/perfusion plate platforms, including a 384-pillar plate with sidewalls and slits (384PillarPlate) and a clear-bottom, 384-deep well plate (384DeepWellPlate) developed for static organoid culture as well as a 36-pillar plate with sidewalls and slits (36PillarPlate) and a 36- perfusion well plate with reservoirs and microchannels (36PerfusionPlate) for perfusion-based organoid culture. Our proposed pillar/perfusion plate platforms combining “3D bioprinting” with “microfluidic-like” features offer several distinctive advantages over more conventional 3D cell culture models and microfluidic models. In particular, the pillar/perfusion plates are compatible with standard 384-well plates and existing high-throughput screening (HTS) equipment (e.g., automated fluorescence microscopes and microtiter well plate readers) already familiar to users, which will significantly lower barriers to entry for commercialization. In the proposed research, human brain organoids (HBOs) derived from induced pluripotent stem cells (iPSCs) are selected as a model system to develop a predictive assessment tool for developmental neurotoxicity (DNT) by compounds including opioid drugs and alcohol. Our core hypotheses are: (i) bioprinted HBOs on the pillar/perfusion plates can maintain key tissue biomarkers by controlling and mimicking in vivo microenvironments and enable high- throughput, high-content cell function analysis; (ii) HBOs on the pillar/perfusion plates can model the influence of drugs and environmental toxicants to neurodevelopmental disorders. The specific aims of the proposed research are to: (1) improve reproducibility of organoid culture via miniature 3D bioprinting technology; (2) establish in situ whole organoid imaging on a pillar plate for high-throughput, predictive compound screening; (3) establish cryopreservation of organoids on the pillar plate. We envision that bioprinted human organoids on the pillar/perfusion plate platforms can be used as promising disease models for screening therapeutic drugs while minimizing the use of animals in drug discovery processes.Project NarrativeThe proposed research facilitates predictive assessment of compounds including chemicals and drug candidates by creating human organoids on pillar/perfusion plate platforms, including a 384-pillar plate with sidewalls and slits (384PillarPlate) and a clear-bottom, 384-deep well plate (384DeepWellPlate) developed for static organoid culture as well as a 36-pillar plate with sidewalls and slits (36PillarPlate) and a 36-perfusion well plate with reservoirs and microchannels (36PerfusionPlate) for perfusion-based organoid culture. Bioprinted organoids on the pillar/perfusion plate platforms will be used as a promising tool for elucidating mechanisms that underlie human diseases. The outcome of this work may help researchers better predict the in vivo toxicity/efficacy of drug candidates, and thus help to decide which compounds are brought forward for lead optimization and the ultimate development of more efficacious and safer drugs. In addition, this research is relevant to the prioritization of industrial and environmental chemicals in terms of their safety and use.

Technology keywords

Not reported

Other awards by this recipient

Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.

Awards with the same topic code

Verified by an exact topic code match. This is not a text-similarity match.

Research funding history

3 SBIR/STTR records share this UEI (2020–2025). Reported award amounts total $1,429,398. Reported amounts are not federal obligations.

Phases: Phase I, Phase II – Direct to Phase II

Agencies: Department of Health and Human Services

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.